Related Experiment Video
Updated: Jun 10, 2026
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Targeting the prostate-specific membrane antigen for prostate cancer therapy
Patrick Bühler1, Philipp Wolf, Ursula Elsässer-Beile
1Department of Urology, Experimental Urology, University of Freiburg, Breisacher Strasse 117, Freiburg, Germany.
Immunotherapy
|July 20, 2010
Summary
New prostate cancer therapies targeting the prostate-specific membrane antigen (PSMA) show promise for advanced disease. Antibody-based treatments are being developed for improved imaging and therapeutic strategies.
Area of Science:
- Oncology
- Immunology
- Radiochemistry
Background:
- Prostate cancer is a significant cause of male mortality.
- Current treatments like surgery, radiotherapy, and hormonal therapy are insufficient for advanced metastatic disease.
- Novel therapeutic strategies are essential for patients with no curative options.
Purpose of the Study:
- To explore the potential of prostate-specific membrane antigen (PSMA) as a therapeutic target.
- To review emerging antibody-based imaging and therapeutic agents targeting PSMA.
- To discuss various treatment modalities including targeted toxins, radiotherapeutics, immunotherapy, and vaccines.
Main Methods:
- Review of current literature on prostate cancer treatments.
- Analysis of PSMA expression patterns in prostate cancer.
- Evaluation of preclinical and clinical data for PSMA-targeted agents.
Main Results:
- Prostate-specific membrane antigen (PSMA) is highly and specifically expressed on prostate cancer cells across all stages.
- PSMA's characteristics make it an ideal target for antibody-based therapies.
- Early clinical trials of anti-PSMA agents are underway.
Conclusions:
- Targeting PSMA offers a promising new avenue for treating advanced prostate cancer.
- Antibody-based strategies, including toxins, radiotherapeutics, and immunotherapies, are under investigation.
- Further development of PSMA-targeted agents could lead to improved outcomes for prostate cancer patients.
